December 7, 2020
Relief, NeuroRx to test aviptadil for treating respiratory failure in Covid-19 patients
Relief Therapeutics and NeuroRx have met the 165 patient enrollment target agreed with the U.S. Food and Drug Administration (FDA) in the ongoing phase 2b/3 trial of RLF-100 (aviptadil) for treating Respiratory Failure in patients with Critical COVID-19.